New drug hopes to ease rare lung condition in children
NCT ID NCT07646860
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests the safety and tolerability of sotatercept in Japanese children aged 1 to 18 with pulmonary arterial hypertension (PAH), a condition where blood vessels in the lungs narrow, making the heart work harder. Participants receive sotatercept injections every three weeks alongside their usual PAH medications. Researchers monitor side effects, how the drug moves through the body, and whether it helps lower resistance in lung blood vessels.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
sotatercept
What this could lead to
If successful, this could provide a new treatment option for children with pulmonary arterial hypertension, potentially improving blood flow and easing strain on the heart.
What could go wrong
This is a small, early-phase study with only 6 participants, so results may not apply to all children. Side effects or lack of benefit are possible.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for PULMONARY ARTERIAL HYPERTENSION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.